Accurate Estimation of In Vivo Inhibition Constants of Inhibitors and Fraction Metabolized of Substrates with Physiologically Based Pharmacokinetic Drug–Drug Interaction Models Incorporating Parent Drugs and Metabolites of Substrates with Cluster Newton Method[§]

Kenta Yoshida, Kazuya Maeda, Akihiko Konagaya, and Hiroyuki Kusuvara

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo (K.Y., K.M., H.K.), and Interdisciplinary Graduate School of Science and Engineering, Tokyo Institute of Technology, Yokohama (K.Y., A.K.), Japan

Received April 3, 2018; accepted August 16, 2018

ABSTRACT

The accurate estimation of “in vivo” inhibition constants (K_i) of inhibitors and fraction metabolized (f_m) of substrates is highly important for drug–drug interaction (DDI) prediction based on physiologically based pharmacokinetic (PBPK) models. We hypothesized that analysis of the pharmacokinetic alterations of substrate metabolites in addition to the parent drug would enable accurate estimation of in vivo K_i and f_m . Twenty-four pharmacokinetic DDIs caused by P450 inhibition were analyzed with PBPK models using an emerging parameter estimation method, the cluster Newton method, which enables efficient estimation of a large number of parameters to describe the pharmacokinetics of parent and metabolized drugs. For each DDI, two analyses were conducted (with or without substrate metabolite data), and the parameter estimates were compared with

each other. In 17 out of 24 cases, inclusion of substrate metabolite information in PBPK analysis improved the reliability of both K_i and f_m . Importantly, the estimated K_i for the same inhibitor from different DDI studies was generally consistent, suggesting that the estimated K_i from one study can be reliably used for the prediction of untested DDI cases with different victim drugs. Furthermore, a large discrepancy was observed between the reported in vitro K_i and the in vitro estimates for some inhibitors, and the current in vivo K_i estimates might be used as reference values when optimizing in vitro–in vivo extrapolation strategies. These results demonstrated that better use of substrate metabolite information in PBPK analysis of clinical DDI data can improve reliability of top-down parameter estimation and prediction of untested DDIs.

Introduction

Pharmacokinetic drug–drug interactions (DDIs) alter the pharmacokinetics of substrate (victim) drugs, consequently leading to adverse reactions that may include lethal events (Huang et al., 2008). For DDIs caused by the inhibition of drug-metabolizing enzymes, the magnitude of the DDI depends on the inhibition constants (K_i) of the inhibitors against the enzymes and the contribution of the inhibited enzyme to the overall elimination of the substrate drugs (f_m) as well as the exposure of the inhibitors at the enzyme active site (Ito et al., 1998; Brown et al.,

2005; Obach et al., 2006; Houston and Galetin, 2008; Hisaka et al., 2010). Therefore, the reliability of these two parameters affects the accuracy of the simulated results of the DDI cases.

The physiologically based pharmacokinetic (PBPK) model has been employed for quantitative analysis of clinically reported DDIs (Rowland et al., 2011; Jones et al., 2015; Wagner et al., 2015; Luzon et al., 2017). With the aim of improving the accuracy of PBPK model-based prediction of DDIs, Kato et al. (2008) determined the in vivo K_i values of multiple inhibitor drugs for cytochrome P450 enzymes (P450) by comprehensive analysis of DDI data. They found that the in vivo K_i estimates were smaller than the in vitro K_i values for many inhibitors. They also found that in vivo K_i values showed an up to 100-fold difference, depending on the clinical data. They suggested that the reproducibility of the clinical data from different study groups and the reliability of the fixed f_m values employed in PBPK analysis based on in vitro data are potential causes of such inconsistencies. In fact, a small

This work was supported by the Japan Society for the Promotion of Science (JSPS), Japan [a Grant-in-Aid for Scientific Research on Innovative Areas 22136001 and a Grant-in-Aid for Scientific Research (S) 24229002].

<https://doi.org/10.1124/dmd.118.081828>.

[§]This article has supplemental material available at dmd.aspetjournals.org.

ABBREVIATIONS: A_e , amount excreted into urine; AUCR, plasma concentration–time curve ratio; C, concentration of drugs; CL_{int} , hepatic intrinsic clearance with regard to unbound concentration; CNM, cluster Newton method; DDI, drug–drug interaction; DDI, University of Washington Metabolism and Transport Drug Interaction Database; F_aF_g , intestinal availability; f_b , protein unbound fraction in blood; f_m , fraction metabolized; I , concentration of inhibitors; k_a , absorption rate constant; $k_{transit}$, transit rate constant in intestine; K_i , inhibition constant for unbound inhibitor concentrations; $K_{i,total}$, inhibition constant for total (bound + unbound) inhibitor concentrations; k_{LI} , transit rate constant to the large intestine; $K_{p,l}$, liver-to-blood concentration ratio; MBI, mechanism-based inhibition; PBPK, physiologically based pharmacokinetic; P450, cytochrome P450; Q, blood flow rate; R_{MBI} , degree of inhibition with mechanism-based inhibitors; $SS_{log,time}$, sum of squares of log residuals; $SS_{log,Y}$, sum of squares of log residuals for the objective function Y; X, amount of drugs.

variation of f_m in a PBPK analysis can have a large impact on the estimated K_i .

The ratio of the area under the plasma concentration–time curve (AUCR) of a substrate drug in the presence of a perpetrator drug to that in its absence can be described as eq. 1, when a perpetrator drug (I_u : its plasma protein unbound concentration) competitively inhibits the specific drug metabolizing enzyme(s) (Khojasteh et al., 2011):

$$\text{AUCR} = \frac{1}{\frac{f_m}{1 + \frac{I_u}{K_i}} + (1 - f_m)} \quad (1)$$

For instance, a 3.3-fold increase in the AUCR of the substrates can be explained either by an f_m of 70% with 99.6% inhibition of the enzyme, or an f_m of 90% with 77% inhibition. The K_i values varied 70-fold in these two cases. In other words, K_i and f_m are susceptible to an identifiability problem.

To overcome these difficulties, we need to include additional information related to in vivo f_m or K_i . In this study, we focused on the concentration–time profiles of substrate drug metabolites. One can expect that less variety in metabolic enzymes is involved in the formation of metabolites compared with the overall elimination of parent drugs because the elimination of parent drugs is often composed of the formation of multiple metabolites. This specificity can be helpful in accurately determining the alteration in metabolic activity by each enzyme.

Our hypothesis was that an analysis of the pharmacokinetic alterations of the specific substrate metabolites in addition to the substrate parent drug would enable accurate estimation of in vivo K_i and f_m . One technical difficulty of this approach is that conventional parameter estimation methods (e.g., Gauss-Newton algorithm) require an estimation of multiple sets of feasible initial parameters to obtain reliable fitted parameters; however, their preparation is laborious and requires a deep understanding of the pharmacokinetics not only for a substrate parent drug but also for the substrate metabolites.

It is challenging to estimate the pharmacokinetic parameters of metabolites due to the paucity of clinical pharmacokinetic data in humans. With this situation in mind, we introduced a new parameter estimation method, which we refer to as the cluster Newton method (CNM) (Yoshida et al., 2013; Aoki et al., 2014). CNM automatically prepares multiple initial parameter sets when the researchers set the broad ranges of the initial parameters, and it suggests multiple sets of fitted parameters as likely solutions. In the present study, we performed PBPK analyses of various DDIs involving the inhibition of P450 enzymes to accurately estimate in vivo K_i and f_m by including substrate metabolite pharmacokinetic information.

Materials and Methods

Definitions of Pharmacokinetic Parameters. The following pharmacokinetic parameters were used throughout this article: C , concentration of drugs; CL_{int} , hepatic intrinsic clearance with regard to unbound concentration; F_aF_g , intestinal availability; f_b , protein unbound fraction in blood; I , concentration of inhibitors; k_a , absorption rate constant; $k_{transit}$, transit rate constant in intestine; K_i , inhibition constant for unbound inhibitor concentrations; $K_{i,total}$, inhibition constant for total (bound + unbound) inhibitor concentrations; k_{LI} , transit rate constant to the large intestine; $K_{p,h}$, liver-to-blood concentration ratio; R_{MBI} , degree of inhibition with mechanism-based inhibitors; Q , blood flow rate; and X , amount of drugs.

The following subscripts were used throughout the article: C, central compartment; H, liver compartment; LI, large intestine; Met, metabolite; Peri, peripheral compartment; and Transit_intes, intestinal transit compartment.

Data Source. University of Washington Metabolism and Transport Drug Interaction Database (DIDB: <http://www.druginteractioninfo.org>) was queried to retrieve in vivo pharmacokinetic interactions involving substrates of

CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A until March 2015. Twenty-four DDI cases that met the following criteria were collected (Tables 1 and 2): (1) concentration–time profiles of parent substrates were available, (2) at least the AUC and/or amount excreted into urine (A_e) of the substrate metabolite were available, and (3) information on the isoforms involved in the formation of the metabolites of interest was available in the DIDB. For inhibitors, the following parameters for all metabolic enzymes were collected via the DIDB: inhibition constant (K_i), inhibitor concentration at half the maximal inhibition potency (IC_{50}), maximal inactivation rate constant (k_{inact}), and apparent inactivation constant ($K_{I,app}$).

PBPK Model Development. PBPK models were constructed to describe the pharmacokinetics of substrates (Fig. 1B) and inhibitors (Fig. 1A). The models incorporated central, peripheral, liver, intestinal, and intestinal transit compartments. Formation of substrate metabolites occurs at a liver compartment and at an intestinal compartment. For the hepatic elimination of substrates, P450 enzyme–specific pathways and inhibition by coadministered drugs were included in the model of a DDI case when the following criteria were met:

1. The enzyme was involved in the metabolism of the substrate, according to the in vitro metabolism data.
2. The inhibitor had predicted an R_1 (competitive inhibition) or R_2 (mechanism-based inhibition [MBI]) value of more than 2 against the enzyme of interest (<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf>), using geometric mean of the reported K_i , IC_{50} , k_{inact} , and $K_{I,app}$.

When the R_2 criterion was met (clarithromycin on CYP3A, fluoxetine on CYP2C19 and CYP3A, or paroxetine on CYP2D6), the potency of the MBI by inhibitors was described with the R_{MBI} parameter in the PBPK model, as described in the next section, under an assumption that the inhibition potency by MBI at the steady-state is constant; otherwise, K_i was used to describe the inhibition potencies of inhibitors on hepatic enzymes.

In addition, the elimination pathways with other P450 enzymes or non-P450 enzymes were included to form “other pathways” in the model. P450 enzyme–specific pathways were further divided into the formation of each substrate metabolite, including “other metabolites” that were not quantified in reported DDIs. Similarly, P450 enzyme–specific and other elimination pathways were included in the eliminations of substrate metabolites.

Intestinal metabolism by CYP3A and its inhibition by coadministered drugs were considered when the following criteria were met:

1. CYP3A was involved in the metabolism of the substrate, according to the in vitro metabolism data.
2. The estimated F_aF_g of the substrate was less than 0.95 (Table 3).
3. The inhibitor used in a clinical study has a predicted R_1 value (using inhibitor concentration of dose/250 ml) of more than 11 against CYP3A <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf> using the geometric mean of the reported K_i and IC_{50} .

The potency of intestinal enzyme inhibition by inhibitors was described with the R_{intes} parameter in our PBPK model as a constant value due to the following reasons/assumptions: 1) our PBPK model does not make an inference on effective intestinal inhibitor concentration, which makes estimation of K_i difficult; and 2) the intestinal inhibition matters mainly at the early time points (before intestinal absorption of substrate drugs is finished), and time-dependent change in the magnitude of intestinal inhibition has less influence on substrate kinetics compared with the inhibition of hepatic enzymes. This assumption is supported by the fact that estimated k_a of all of the substrates has geometric mean of $\geq 0.6 \text{ hour}^{-1}$ (a half-life of approximately 1 hour or less).

Elimination pathways with other P450 enzymes or non-P450 enzymes were included to form “other pathways” in the model.

Simulations with PBPK Models. All the simulations were performed with the PBPK models described in Fig. 1 and in the following equations. First, hepatic or renal clearance and intestinal kinetic constants were calculated, where i , j , or k represent P450 enzymes, metabolites, or inhibitors, and a single prime (') denotes the parameter values when inhibitor(s) were coadministered:

TABLE 1
List of inhibitors analyzed in this study

Initial parameter settings and the results of the analyses are summarized in the corresponding figures and tables.				
Drug	Administration	Objective Function	Supplemental Data	Reference (PubMed ID)
Clarithromycin ^a				
Fluconazole	Single intravenous/oral	AUC _{inf}	Table 1, Fig. 1	2540363
Fluoxetine	Single/multiple oral	AUC _{inf}	Tables 2.1, 2.2; Figs. 2.1, 2.2	1544284
Fluvoxamine	Single oral	AUC _{inf}	Table 3, Fig. 3	8499580
Itraconazole	Multiple oral	AUC _{inf}	Table 4, Fig. 4	2848442
Paroxetine ^a				
Quinidine	Single oral	AUC _{inf}	Table 5, Fig. 5	7693389
Voriconazole	Multiple oral	AUC _{inf}	Table 6, Fig. 6	1629172

AUC, area under the plasma concentration–time curve; AUC_{inf}, AUC from time zero to infinity.

^aPlasma concentration–time profiles were not considered in the analyses of DDI and were not analyzed with PBPK models because the inhibition of CYP enzymes involved mechanism-based inhibition.

$$f_B \text{CL}_{\text{CYP}_A} = f_B \text{CL}_{\text{int}} \cdot \frac{\text{CL}_{\text{CYP}_A} / \text{CL}_{\text{other}}}{\sum_i (\text{CL}_{\text{CYP}_i} / \text{CL}_{\text{other}}) + 1} \quad (2)$$

$$f_B \text{CL}_{\text{other}} = f_B \text{CL}_{\text{int}} \cdot \frac{1}{\sum_i (\text{CL}_{\text{CYP}_i} / \text{CL}_{\text{other}}) + 1} \quad (3)$$

$$f_B \text{CL}_{\text{CYP}_A, \text{Met}_a} = f_B \text{CL}_{\text{CYP}_A} \cdot \frac{\text{CL}_{\text{CYP}_A, \text{Met}_a} / \text{CL}_{\text{CYP}_A, \text{other}}}{\sum_j (\text{CL}_{\text{CYP}_A, \text{Met}_j} / \text{CL}_{\text{CYP}_A, \text{other}}) + 1} \quad (4)$$

$$f_B \text{CL}_{\text{other}, \text{Met}_a} = f_B \text{CL}_{\text{other}} \cdot \frac{\text{CL}_{\text{other}, \text{Met}_a} / \text{CL}_{\text{other}, \text{other}}}{\sum_j (\text{CL}_{\text{other}, \text{Met}_j} / \text{CL}_{\text{other}, \text{other}}) + 1} \quad (5)$$

$$f_B \text{CL}_{\text{other}, \text{other}} = f_B \text{CL}_{\text{other}} \cdot \frac{1}{\sum_j (\text{CL}_{\text{other}, \text{Met}_j} / \text{CL}_{\text{other}, \text{other}}) + 1} \quad (6)$$

$$f_B \text{CL}'_{\text{CYP}_A, \text{Met}_a} = f_B \text{CL}_{\text{CYP}_A, \text{Met}_a} \cdot \frac{1}{1 + \sum_k (I_{H,k} / K_{i, \text{total}, k, \text{CYP}_A})} \cdot \frac{1}{\prod_k R_{\text{MBI}, k, \text{CYP}_A}} \quad (7)$$

$$\text{CL}_R = \frac{Q_R \text{CL}_{R, \text{int}, \text{app}}}{Q_R + \text{CL}_{R, \text{int}, \text{app}}} \quad (8)$$

$$k_{\text{LI}} = k_a \cdot \frac{1 - F_a F_g}{F_a F_g} \cdot \frac{1}{\sum_i (k_{\text{CYP}3A, \text{CYP}_i} / k_{\text{LI}}) + 1} \quad (9)$$

$$k_{\text{CYP}3A, \text{Met}_a} = k_a \cdot \frac{1 - F_a F_g}{F_a F_g} \cdot \frac{k_{\text{CYP}3A, \text{CYP}_A} / K_{\text{LI}}}{\sum_i (k_{\text{CYP}3A, \text{CYP}_i} / K_{\text{LI}}) + 1} \quad (10)$$

$$k'_{\text{CYP}3A, \text{Met}_a} = k_{\text{CYP}3A, \text{Met}_a} \cdot \frac{1}{\prod_k R_{\text{int}, \text{CYP}3A, k}} \quad (11)$$

Using these parameters, the following ordinary differential equations were solved numerically:

Equations for Substrates.

Central compartment (C):

$$V_C \frac{dC_C}{dt} = Q_H \frac{C_H}{K_{P,H}} + k_{21} X_{\text{Peri}} - (Q_H + \text{CL}_{12} + \text{CL}_R) C_C \quad (12)$$

Peripheral compartment (Peri):

$$\frac{dX_{\text{Peri}}}{dt} = -k_{21} X_{\text{Peri}} + \text{CL}_{12} C_C \quad (13)$$

Intestinal and intestinal transit compartment (Transit_{intes}):

$$\frac{dX_{\text{Transit}_\text{intes}}}{dt} = -k_{a, \text{transit}} X_{\text{Transit}_\text{intes}} \quad (14)$$

$$\frac{dX_{\text{Intestine}}}{dt} = k_{a, \text{transit}} X_{\text{Transit}_\text{intes}} - \left(k_a + k_{\text{LI}} + \sum_j k_{\text{CYP}3A, \text{Met}_j} \right) X_{\text{Intestine}} \quad (15)$$

Liver compartment (H):

$$V_H \frac{dC_H}{dt} = Q_H \cdot \left(C_C - \frac{C_H}{K_{P,H}} \right) - \sum_i \sum_j f_B \text{CL}_{\text{CYP}_i, \text{Met}_j} \cdot \frac{C_H}{K_{P,H}} \quad (16)$$

Equations for Metabolite (a) of Substrates.

Central compartment:

$$V_C \frac{dC_C}{dt} = Q_H \frac{C_H}{K_{P,H}} + k_{21} X_{\text{Peri}} - (Q_H + \text{CL}_{12} + \text{CL}_R) C_C \quad (17)$$

Peripheral compartment:

$$\frac{dX_{\text{Peri}}}{dt} = -k_{21} X_{\text{Peri}} + \text{CL}_{12} C_C \quad (18)$$

Intestinal compartment:

$$\frac{dX_{\text{Intestine}}}{dt} = k_{\text{CYP}3A, \text{Met}_a, \text{parent}} X_{\text{Transit}_\text{intes}, \text{parent}} - k_a X_{\text{Intestine}} \quad (19)$$

Liver compartment:

$$V_H \frac{dC_H}{dt} = Q_H \cdot \left(C_C - \frac{C_H}{K_{P,H}} \right) - \sum_i f_B \text{CL}_{\text{CYP}_i} \cdot \frac{C_H}{K_{P,H}} + \sum_i f_B \text{CL}_{\text{CYP}_i, \text{Met}_a, \text{parent}} \cdot \frac{C_{H, \text{parent}}}{K_{P,H}} \quad (20)$$

Equations for Inhibitors.

Central compartment:

$$V_C \frac{dC_C}{dt} = Q_H \frac{C_H}{K_{P,H}} + k_{21} X_{\text{Peri}} - (Q_H + \text{CL}_{12} + \text{CL}_R) C_C \quad (21)$$

Peripheral compartment:

$$\frac{dX_{\text{Peri}}}{dt} = -k_{21} X_{\text{Peri}} + \text{CL}_{12} C_C \quad (22)$$

Intestinal and intestinal transit compartment:

$$\frac{dX_{\text{Transit}_\text{intes}}}{dt} = -k_{a, \text{transit}} X_{\text{Transit}_\text{intes}} \quad (23)$$

$$\frac{dX_{\text{Intestine}}}{dt} = k_{a, \text{transit}} X_{\text{Transit}_\text{intes}} - \frac{k_a}{F_a F_g} X_{\text{Intestine}} \quad (24)$$

Liver compartment:

$$V_H \frac{dC_H}{dt} = Q_H \cdot \left(C_C - \frac{C_H}{K_{P,H}} \right) - f_B \text{CL}_{\text{int}} \cdot \frac{C_H}{K_{P,H}} \quad (25)$$

Parameter Settings. The following physiologic and pharmacokinetic parameters were fixed throughout the analyses: Q_H , V_H , dose, and $F_a F_g$. The $F_a F_g$ was calculated with eq. 26 (Table 3):

$$F_a F_g = F \cdot \frac{Q_H}{Q_H - (\text{CL}_{\text{tot}} - \text{CL}_R)} \quad (26)$$

If the calculated $F_a F_g$ was larger than 0.95, we assumed $F_a F_g$ was equal to 1. The $K_{p,h}$ of the inhibitors was fixed to predicted values by methods reported

TABLE 2
List of drug–drug interactions analyzed in this study

Initial parameter settings and the results of the analyses are summarized in the corresponding figures and tables.

Substrates	Metabolites	Inhibitors	Putative Enzyme(s) Involved	AUCR	ID Number	Additional Data ^d	Objective Function		Reference (PubMed ID)
							Parent	Metabolite	
Chlorpromazine	7-Hydroxy chlorpromazine	Quinidine (166 mg)	CYP2D6, CYP3A	1.40	1	Table S7, Fig. S7	AUC _{inf}	AUC _{inf}	8739822
Desipramine	2-Hydroxy desipramine	Fluoxetine (60 mg)	CYP2D6	2.58 ^b	2	Table S8.1, Fig. S8.1	AUC _{inf}	A _e	1544284
				10.6 ^c	3	Table S8.2, Fig. S8.2			
Fentanyl	Norfentanyl	Fluconazole (200 mg)	CYP3A	1.26	4	Table S9.1, Fig. S9.1	AUC _{inf}	AUC _{inf}	17987285
		Voriconazole (200 mg)	CYP3A	1.39	5	Table S9.2, Fig. S9.2			
Flurbiprofen	4'-Hydroxy flurbiprofen	Fluconazole (200 mg)	CYP2C9	1.75	6	Fig. 2/Table S.10.1, Fig. S10.1	AUC	AUC	22943633
				2.02	7	Table S10.2, Fig. S10.2			23047652
Hydrocodone	Hydromorphone	Quinidine (83 mg)	CYP2D6	1.21	8	Table S11, Fig. S11	AUC _{inf}	AUC _{inf}	7693389
Imipramine	2-Hydroxy imipramine, desipramine	Fluoxetine (60 mg)	CYP2D6, CYP2C19, CYP3A	2.08 ^b	9	Table S12.1, Fig. S12.1	AUC _{inf}	AUC _{inf} /A _e	1544284
				3.56 ^c	10	Table S12.2, Fig. S12.2			
Lansoprazole	5-Hydroxy lansoprazole, lansoprazole sulfone	Fluvoxamine (25 mg)	CYP2C19	4.00 ^d	11	Table S13.1, Fig. S13.1	AUC _{inf}	AUC _{inf}	15496639
				2.50 ^e	12	Table S13.2, Fig. S13.2			
		Clarithromycin (400 mg)	CYP3A	1.38 ^d	13	Table S13.3, Fig. S13.3			15752376
				1.76 ^e	14	Table S13.4, Fig. S13.4			
				1.81 ^f	15	Table S13.5, Fig. S13.5			
Losartan	EXP-3174	Fluconazole (200 mg)	CYP2C9, CYP3A	1.69	16	Table S14.1, Fig. S14.1	AUC _{inf}	AUC _{inf}	9357393
				1.27	17	Table S14.2, Fig. S14.2			9551703
Omeprazole	5-Hydroxy omeprazole, omeprazole sulfone	Fluvoxamine (25 mg)	CYP2C19	5.62 ^d	18	Table S15.1, Fig. S15.1	AUC _{inf}	AUC/AUC _{inf}	15025747
				2.38 ^e	19	Table S15.2, Fig. S15.2			
Oxycodone	Noroxycodone, oxymorphone	Quinidine (166 mg)	CYP2D6	1.13	20	Table S16.1, Fig. S16.1	AUC _{inf}	AUC/AUC _{inf}	9871425
		Voriconazole (200 mg)	CYP3A	3.57	21	Table S16.2, Fig. S16.2			18836708
		Itraconazole (200 mg)	CYP3A	2.43	22	Table S16.3, Fig. S16.3			20076952
		Paroxetine (20 mg)	CYP2D6	1.11	23	Table S16.4, Fig. S16.4			20642550
Ropivacaine	(S)-2',6'-pipecoloxylidide	Itraconazole (200 mg)	CYP3A	1.23	24	Table S17, Fig. S17	AUC _{inf}	AUC	11322176

AUC, area under the plasma concentration–time curve; AUC_{inf}, AUC from time 0 to infinity.

^aTables and figures indicated with an S are found in the supplemental data.

^bFluoxetine single dose.

^cFluoxetine multiple dose.

^dCYP2C19 extensive metabolizer (EM).

^eCYP2C19 intermediate metabolizer (IM).

^fCYP2C19 poor metabolizer (PM).

elsewhere (Rodgers et al., 2005; Rodgers and Rowland, 2006) using clogP and pKa obtained with Scifinder Scholar (Chemical Abstracts Service, Columbus, OH). All the other parameters were estimated by CNM.

The initial ranges of V_c were set as 0.0817–7.43 l/kg because the lower boundary was set to be 10% higher than the lowest limit of parameter value (blood volume = 0.0743 l/kg) (Davies and Morris, 1993) to avoid the infinite transformed initial value (see “Transformations of Parameters”) when the initial parameter is equal to its lower limit, except for fluoxetine, desipramine, and imipramine (0.743–74.3 l/kg) where large elimination half-lives were observed. The initial ranges of k_a were set as 0.2–6.0 hour^{−1}, considering a gastric emptying rate of 6 hour^{−1} (Ito et al., 1998). The same ranges were used for $k_{transit}$.

The initial ranges of f_BCL_{int} were set as 1/10-fold to 10-fold of the total body clearance of substrates (control group) or inhibitors. When the peripheral compartment is needed to reproduce the observed concentration–time profiles, the same ranges were used for CL_{12} and k_{21} as f_BCL_{int} . For fluconazole, larger ranges of CL_{12} and k_{21} were needed to reproduce clinical observations. These ranges were also used for the f_BCL_{int} , CL_{12} , k_{21} , and $CL_{R,int,app}$ (if renal clearance is unknown) of substrate metabolites, except for EXP3194 (a metabolite of losartan) and noroxycodone (a metabolite of oxycodone), where smaller ranges were needed to reproduce clinical observations. We used 0.03–30 as the initial range for the ratios of CYP enzyme-selective pathways to the other pathway in the overall elimination of substrates, or the ratios of the substrate metabolites' formations to the other pathway in the CYP enzyme-selective pathways; the

TABLE 3

Summary of calculated pharmacokinetic parameters fixed in PBPK analyses

If not indicated, pharmacokinetic parameters were derived from the University of Washington Metabolism and Transport Drug Interaction Database (DIDB).

Compound	$K_{p,h}$ ^a	$F_a F_g$	R_B	f_B	References (PubMed ID)
Substrates					
Chlorpromazine	– ^b	0.685	0.78		10534321, ^c
Desipramine	– ^b	1.03 ^d	0.89		3365915
Fentanyl	– ^b		1 ^e		6121896
Flurbiprofen	– ^b	>1 ^d	0.56		^f
Hydrocodone	– ^b	1 ^e	1 ^e		
Imipramine	– ^b	0.97	1.1		6429693, 10534321
Lansoprazole	– ^b	1.97 ^d	0.56		8803522, 20056146
Losartan	– ^b	0.896	0.6 ^g		8529329
Omeprazole	– ^b	1.83 ^d	0.58		3858978
Oxycodone	– ^b	1.05 ^d	1.3		19417618, 22798176
Ropivacaine	– ^b		0.69		11322176
Inhibitors					
Fluconazole	0.647	– ^b	1	0.89	18483837
Fluoxetine	13.6	0.722	0.96	0.063	18483837
Fluvoxamine	12.1	0.971	1	0.23	18483837
Itraconazole	6.38	0.885	0.58	0.062	18483837, 17495874
Quinidine	11.6	0.869	0.92	0.14	18483837
Voriconazole	0.562	1	1 ^e	0.42	

^a $F_a F_g$, intestinal availability; R_B , blood-to-plasma concentration ratio.^bPredicted with the reported in silico methods (Rodgers et al., 2005; Rodgers and Rowland, 2006).^cEstimated in the following PBPK analysis.^dThummel et al. 2010.^e $F_a F_g$ calculated to be >1 was fixed as 1 for PBPK analysis.^fAssumed to be equal to 1.^gTono et al. 1992.^hAssumed to be equal to 0.6.

Results

Collection of Information of DDIs and Metabolic Enzymes that Interact with Substrates or Inhibitors. Twenty-four cases of clinical DDIs from 17 reports with eight inhibitors (Tables 1 and 2) in which pharmacokinetic alterations of the substrate drug metabolites as well as substrate parent drugs were reported were collected from the DIDB (Hachad et al., 2010). AUCR of substrates ranged from 1.11 to 10.6 (mean: 2.49, median: 1.79). Our literature review for in vitro data using the DIDB suggested the formations of substrate metabolites quantified in the DDI reports were mediated by specific CYP enzymes, except for the formations of 7-hydroxy chlorpromazine (CYP1A2 and 2D6), 5-hydroxy lansoprazole (CYP2C19 and 3A), 5-hydroxy omeprazole (CYP2C19 and 3A), and EXP3194 (CYP2C9 and 3A).

Evaluation of the in vitro inhibition potency of the inhibitors by the static model with in vitro inhibition parameters and clinical inhibitor concentration in plasma (see *Materials and Methods*) suggested that there were 4, 6, 8, and 13 DDI cases involving CYP2C9, CYP2C19, CYP2D6, and CYP3A as putative enzymes (Table 2). It also suggested that the inhibitor affected the activity of only one CYP enzyme in the liver in all the collected DDIs, except for the effect of fluconazole on losartan elimination (CYP2C9 and CYP3A) and fluoxetine on imipramine elimination (CYP2C19, CYP 2D6, and CYP3A). The effects of clarithromycin on CYP3A, fluoxetine on CYP2C19 and CYP3A, and paroxetine on CYP2D6 were reported to involve MBI, whereas the others involved reversible inhibitions.

Analyses of Inhibitor Pharmacokinetic Profiles with PBPK Models. The blood concentration–time profiles of inhibitors in collected DDIs (Table 1) were analyzed using PBPK models (Fig. 1a). We obtained 1000 or 2000 parameter sets reproducing the objective values (minimizing $SS_{\log,Y}$) with CNM. Among these, we obtained parameter sets that could reproduce the time profiles of inhibitor blood concentrations (minimizing $SS_{\log,time}$) (Supplemental Figs. 1–6; Supplemental Tables 1–6).

The geometric coefficient of variation (CV) of $f_B CL_{int}$ was small (less than 20%) for all inhibitors after the parameter estimations using AUC_{inf} as an objective function, particularly when the single-dose pharmacokinetics were analyzed. In the case of fluconazole, for which the time profiles after oral and intravenous administration were simultaneously analyzed, the geometric CV of $F_a F_g$ was small (2.14%). The geometric CV of most of the other parameters was large (>100% in many cases), suggesting that point estimates of these parameters were not possible only from clinical DDI data.

Analyses of the Effects of Inhibitors on Pharmacokinetic Profiles of Substrates with PBPK Models. The effects of inhibitors on blood concentration–time profiles of substrates in collected DDIs (Table 2) were analyzed using PBPK models (Fig. 1B), with or without including substrate metabolite pharmacokinetic profiles in the analyses. The urinary accumulation of substrate metabolites was analyzed when systemic exposure data were not available (hydroxyl metabolites of imipramine and desipramine). We obtained 1000 or 2000 parameter sets reproducing the objective values (minimizing $SS_{\log,Y}$) with CNM. Among these, we obtained parameter sets that could reproduce time profiles of the blood concentrations of the substrate parent drug and substrate metabolite (minimizing $SS_{\log,time}$) (Fig. 2; Supplemental Figs. 7–17; Supplemental Tables 7–17).

The geometric CV of the $f_B CL_{int}$ values was small for all cases of analysis (mostly around or less than 20%), regardless of whether the information on the substrate metabolite was included in the analysis. In 17 out of 24 cases, inclusion of the substrate metabolite information improved the parameter estimation for K_i and f_m , as suggested by the smaller geometric CV of parameter estimates (Fig. 3). Conversely, inclusion of the substrate metabolite information in the analysis had a smaller effect on the accuracy of the estimated f_m and K_i in DDIs between chlorpromazine and quinidine, lansoprazole and fluvoxamine, losartan and fluconazole, and omeprazole and fluvoxamine. The geometric CV of most of the other parameters was large (>100% in many cases), suggesting that point estimates of these parameters were not possible.

Cross-Study Comparison and Comparison with In Vitro Estimates for f_m . Among the DDI cases for which inclusion of substrate metabolite information improved reliability of K_i or f_m estimates (Fig. 3A), f_m of substrates and K_i of inhibitors were compared with each other (Supplemental Fig. 18; Tables 4 and 5). The estimated values of f_m under multiple conditions (different inhibitors or doses of inhibitors) were consistent for desipramine, flurbiprofen, imipramine, and oxycodone (Supplemental Fig. 18; Tables 4 and 5).

On the other hand, the f_m values of fentanyl estimated from two different DDI cases were not equivalent. The estimated f_m of one CYP enzyme in the overall eliminations of substrates was also in fair agreement with in vitro estimates, both for enzymes with a large contribution [CYP2C9 for flurbiprofen (Yamazaki et al., 1998), CYP2D6 for desipramine (McGinnity et al., 2008), and CYP3A for oxycodone (Lalovic et al., 2004)] and those with a small-to-moderate contribution [CYP2D6 for hydrocodone (Hutchinson et al., 2004), imipramine (McGinnity et al., 2008), or oxycodone (Lalovic et al., 2004), and CYP3A for fentanyl (Guillon et al., 1997), lansoprazole (Naritomi et al., 2004), or ropivacaine (Ekström and Gunnarsson, 1996)].

Cross-Study Comparison and Comparison with In Vitro or Previous PBPK Estimates for K_i . The estimated in vivo K_i in the studies where metabolite information improved the parameter estimates was compared with each other and with in vitro K_i . Because $K_{i,total}$ in the PBPK model was defined against hepatic total (bound + unbound) inhibitor concentration, in vivo unbound K_i was calculated for comparison as $f_B \times (K_{i,total}/K_{p,h})$, assuming that the unbound inhibitor

Fig. 2. Simulated and reported blood concentration–time profiles (A and B) and estimated parameter distributions (C and D) after the analyses of DDI between flurbiprofen and fluconazole (Hanley et al., 2013), with (A and C) or without (B and D) including the substrate metabolites' pharmacokinetic alterations as a typical example of the results of the analyses, and a list of parameters estimated by CNM (E). (A and B) Lines in upper and lower panels represent simulated blood concentration–time profiles with all the parameter sets reproducing objective functions (AUC or Ae as summarized in Tables 1 and 2) and the top three parameter sets best reproducing concentration–time profiles, respectively (see “Parameter Estimations with CNM” in *Materials and Methods*). The orange circles represent the observed time profiles. (C and D) Blue and yellow lines represent the estimated parameter values for all the parameter sets reproducing AUCs and 10 parameter sets reproducing concentration–time profiles, respectively. (E) List of parameters estimated by CNM with corresponding ID numbers (ID1: parameters for analysis with substrate metabolite, ID2: parameters for analysis without substrate metabolite). Parent: flurbiprofen, Metabolite 1: 4'-hydroxy flurbiprofen, Inhibitor: fluconazole. CL_{R,int,app}, renal apparent intrinsic clearance; CL₁₂, transport clearance from central to peripheral compartment; k_{21} , rate constant from peripheral to central compartment.

concentration in the hepatocyte was the same as the unbound hepatic blood concentration ($K_{p,H} = f_B/f_T$).

As for the same combinations of inhibitors and CYP enzymes, estimated K_i by the analyses of different DDIs showed similar values among the different reports (Supplemental Fig. 18; Tables 4 and 5). In all cases where comparison was possible, the interstudy variation of the obtained K_i was narrower than the reported ranges obtained from the previous PBPK analyses of clinical DDIs (Kato et al., 2008). The obtained K_i of fluconazole for CYP2C9 or CYP3A and voriconazole for CYP3A was comparable to the median of the collected in vitro K_i , whereas the K_i of fluoxetine for CYP2D6, itraconazole on CYP3A, and quinidine for CYP2D6 was 100–1000-fold lower than the in vitro K_i .

Discussion

In this study, we aimed to accurately estimate the two most important parameters, K_i and f_m , for determining the degree of pharmacokinetic DDIs (Brown et al., 2005; Obach et al., 2006), based on clinical DDI data where pharmacokinetic alterations of not only substrates but also substrate metabolites has been analyzed. Because some substrate metabolites are produced by a specific enzyme, we hypothesized that use of the substrate metabolites' pharmacokinetic profiles can improve

an estimation of the effect of inhibitors on each CYP enzyme in vivo, leading to accurate estimations of the above two parameters.

First, we determined the pharmacokinetic parameters for the inhibitors. Then, using the fixed parameter sets, we performed PBPK analyses of the substrate parent drugs and/or substrate metabolites. As shown in Fig. 2, multiple solutions (i.e., parameter sets) could account for the time profiles of the blood concentration of substrates and their metabolites. Some parameters are convergent across the solutions, whereas additional information or constraint is necessary for the other parameters to be convergent.

We estimated the f_BCL_{int} of both substrates and inhibitors with a small geometric CV among these 30 parameter sets (Supplemental Figs. 1–17). Because we estimated the parameters to reproduce AUC_{inf} or AUC with CNM, the small geometric CV of f_BCL_{int} in all the substrates and inhibitors was reasonable. By contrast, the estimated f_BCL_{int} of the substrate metabolites showed a large geometric CV (>100% in most cases). Because exposure of the substrate metabolites is determined not only by their elimination rate but also by the formation rate, multiple solutions are allowed to account for the AUC of the substrate metabolites.

As we hypothesized, the estimated f_m and K_i values showed smaller geometric CVs for many (17 out of 24) studies when the pharmacokinetics

Fig. 3. Comparison of the coefficient of variation for f_m and $K_{i, total}/R_{MBI}$ estimates, with or without including substrate metabolites' pharmacokinetic profiles in the PBPK analyses. (a) DDI cases for which inclusion of substrate metabolite information reduced the geometric CV of these parameters by at least 2-fold. (b) DDI cases for which inclusion of substrate metabolite information did not reduce the geometric CV. Closed circles and open triangles represent the geometric CV of f_m or $K_{i, total}/R_{MBI}$ estimated with and without including substrate metabolites' pharmacokinetic profiles, respectively. ID of studies analyzed corresponds to those listed in Table 2. CV, coefficient of variation; R_{MBI} , degree of inhibition with mechanism-based inhibitors.

of both the parent drugs and the metabolites of substrates were analyzed, compared with those estimated when only the pharmacokinetics of the parent substrates were analyzed (Fig. 3). These parameters were reliably estimated even from DDIs in which the parent AUCR <1.5 (fentanyl-fluconazole or voriconazole, hydrocodone-quinidine, oxycodone-quinidine or paroxetine, ropivacaine-itraconazole), suggesting that the substrate metabolite can be a novel source of information for DDI analyses.

The K_i obtained from the analyses of multiple clinical DDIs showed small variation across the reports when the same combinations of inhibitors and target CYP enzymes were examined (Fig. 4; Supplemental Fig. 18; Tables 4 and 5). Moreover, similar K_i values of fluoxetine were obtained in the clinical studies where fluoxetine was given in single and multiple doses (Fig. 4). Such small interstudy variations in estimated f_m and K_i suggest the extrapolatability of these parameters to untested scenarios (different substrate/inhibitor/dosing regimen) and may guarantee the reasonable prediction of DDIs in future studies.

On the other hand, this approach has some limitations. For several DDIs, the inclusion of substrate metabolite information in the analyses could not substantially contribute to reducing the geometric CV in estimated f_m and K_i , such as DDIs between chlorpromazine and quinidine, lansoprazole and fluvoxamine, losartan and fluconazole, or

omeprazole and fluvoxamine. The common characteristics of these DDIs are that multiple isoforms of CYP enzymes catalyze the formation of the substrate metabolites. Thus, uncertainty in the contribution of enzymes may inhibit convergence of f_m and K_i and additional information is needed, such as the contribution of each CYP isoform to substrate metabolite formation.

The estimated K_i values were compared with those reported by Kato et al. (2008) and those determined in vitro (Fig. 4). Interstudy variabilities in the estimated K_i were narrower than those obtained by conventional PBPK analyses. When compared with in vitro K_i , the estimated values for two inhibitors (fluconazole and voriconazole) were comparable to the median of collected in vitro K_i (Fig. 4). For fluoxetine, itraconazole, and quinidine, the estimated K_i was much lower than the in vitro K_i (Fig. 4). For these inhibitors, predictions of DDIs using in vitro K_i would result in underestimations of the degree of DDIs, as pointed out previously elsewhere (Isoherranen et al., 2004; Lutz and Isoherranen, 2012).

Kato et al. (2008) previously suggested that in vivo K_i was generally smaller than in vitro experimental K_i , whose discrepancies apparently depend on the lipophilicity of substrates. In our analyses, especially for highly lipophilic itraconazole, our obtained K_i was closer to the in vivo K_i reported by Kato et al. (2008) rather than

TABLE 4

Estimated parameter values for f_m for DDI cases

The table only includes DDI cases for which the inclusion of substrate metabolite information improved the geometric CV (Fig 3A). Parameter estimates represent summary statistics of 30 parameter sets reproducing concentration–time profiles (low $SS_{log,time}$). Refer to Table 2 for details of DDI information with corresponding ID number.

Substrates	Inhibitors	Isoforms for Parameters	ID Number	Geometric Mean	Geometric CV (%)
Desipramine	Fluoxetine	CYP2D6	2 ^a	0.995	0.578
			3 ^b	0.959	0.543
Fentanyl	Fluconazole	CYP3A	4	0.472	9.59
	Voriconazole	CYP3A	5	0.732	12.8
Flurbiprofen	Fluconazole	CYP2C9	6	0.945	7.99
			7	0.964	5.91
Hydrocodone	Quinidine	CYP2D6	8	0.512	27.7
Imipramine	Fluoxetine	CYP2D6	9 ^a	0.697	3.26
			10 ^b	0.752	1.32
Lansoprazole	Clarithromycin	CYP3A	13 ^c	0.318	13.6
			14 ^d	0.483	8.46
			15 ^e	0.662	23.4
Oxycodone	Quinidine	CYP2D6	20	0.253	6.44
	Voriconazole	CYP3A	21	0.826	1.23
	Itraconazole	CYP3A	22	0.845	4.35
	Paroxetine	CYP2D6	23	0.184	21.5
Ropivacaine	Itraconazole	CYP3A	24	0.338	6.16

CV, coefficient of variation.

^aFluoxetine single dose.^bFluoxetine multiple dose.^cCYP2C19 extensive metabolizer (EM).^dCYP2C19 intermediate metabolizer (IM).^eCYP2C19 poor metabolizer (PM).

in vitro K_i . The inconsistency of the in vitro and in vivo K_i values may be attributable to the following mechanisms: the additional contribution of P-glycoprotein inhibition (Benet et al., 2004), inaccurate estimations of blood unbound fractions of inhibitors, or incubation buffer for in vitro experiments (Thompson et al., 1988; Arredondo et al., 1999; Templeton et al., 2008), extensive accumulation of inhibitors into hepatocytes as seen in itraconazole (Yamano et al., 1999), or additional inhibition by inhibitor metabolites (Otton et al., 1993; Ching et al., 1995; Isoherranen et al., 2004; Templeton et al., 2008; Isoherranen et al., 2009; Lutz and Isoherranen, 2012).

In the reports cited in this study, plasma concentrations of inhibitor metabolites were not measured, and the contribution of inhibitor metabolites was not taken into account in the PBPK analysis. Including

such information may partly address the observed inconsistencies. Furthermore, due to the limited available data for each inhibitor with different experimental conditions, we did not exclude the in vitro studies that did not measure the unbound fraction of inhibitors in an incubation buffer, which could partly explain the interstudy variation of in vitro K_i values (Fig. 4). Interestingly, the lowest in vitro K_i of itraconazole (1 nM) was obtained in an experiment with a low microsome concentration in the incubation buffer (0.025 mg/ml) after correction with the unbound fraction (Isoherranen et al., 2004). This result appears to support the importance of accurately estimating the effective inhibitor concentration in the incubation buffer. For CYP3A, it is also possible that K_i of inhibitors sometimes depend on the substrates tested (Fowler and Zhang, 2008). We will be able to partly bridge the gap between

TABLE 5

Estimated parameter values for K_i for DDI cases

The table only includes DDI cases for which the inclusion of substrate metabolite information improved the geometric CV (Fig 3A). Parameter estimates represent summary statistics of 30 parameter sets reproducing concentration–time profiles (low $SS_{log,time}$). Refer to Table 2 for details of DDI information with corresponding ID number.

Inhibitors	Substrates	Isoforms for Parameters	ID Number	Geometric Mean (μ M)	Geometric CV (%)
Fluconazole	Fentanyl	CYP3A	4	7.73	14.9
	Flurbiprofen	CYP2C9	6	17	4.64
			7	19.9	5.51
Fluoxetine	Desipramine	CYP2D6	2 ^a	0.000195	14.5
			3 ^b	0.000127	5.09
	Imipramine		9 ^a	0.000177	7.9
			10 ^b	0.000149	4.17
Itraconazole	Oxycodone	CYP3A	22	0.000115	7.67
	Ropivacaine		24	0.000103	3.45
Quinidine	Hydrocodone	CYP2D6	8	0.0000977	37.4
	Oxycodone		20	0.000552	41.8
Voriconazole	Oxycodone	CYP3A	5	1.71	47.1
			21	0.535	17

CV, coefficient of variation.

^aFluoxetine single dose.^bFluoxetine multiple dose.

Fig. 4. Comparison of the estimated $K_{i,\text{unbound}}$ with reported values obtained with in vitro experiments or with conventional PBPK analyses of drug-drug interactions caused by the inhibition of CYP2C9 by fluconazole (A), CYP3A by fluconazole (B), CYP2D6 by fluoxetine (C), CYP3A by itraconazole (D), CYP2D6 by quinidine (E), and CYP3A by voriconazole (F) without substrate metabolites' pharmacokinetic information. Circles represent $K_{i,\text{unbound}}$ for the estimated parameter sets with 30 lowest $\text{SS}_{\log,\text{time}}$ values with PBPK models including substrate metabolites' pharmacokinetic profiles. Each square represents the reported in vitro $K_{i,\text{unbound}}$ in a report collected from the University of Washington Metabolism and Transport Drug Interaction Database (DIDB). Bars represent the maximum, geometric mean, and minimum values of estimated $K_{i,\text{unbound}}$ by analyzing drug-drug interactions with PBPK models in the previous report by Kato et al. (2008). $K_{i,\text{unbound}}$, inhibition constant with regard to unbound inhibitor concentration.

in vitro and in vivo K_i for more accurate predictions of clinical DDIs by carefully optimizing our in vitro experimental approaches.

To predict the impact of DDIs on the pharmacokinetics of new investigational drugs, the contribution of enzymes and transporters must be evaluated accurately. Our results indicated that the f_m values determined by our approach under multiple conditions were estimated to be consistent in most cases (four out of five compounds with multiple DDI studies available for comparison; Supplemental Fig. 18 and Tables 4 and 5), supporting the reliability of the in vivo f_m values

of substrates we obtained. As for fentanyl, whose estimated f_m values depended on the reported DDI cases, the original DDI study reported a similar magnitude of change in the parent and metabolite AUC between the voriconazole and fluconazole, while the concentration-time profiles of norfentanyl appeared to be different (Saari et al., 2008). This inconsistency might have led to different estimates of f_m in two DDI cases.

We must be careful about quantitatively extrapolating in vitro observations into in vivo parameters for new investigational drugs.

There are two major difficulties in such extrapolations. The first is that in most of these studies the contribution of each CYP enzyme in vitro was estimated by investigating the formation of one or a few metabolite(s) but not the disappearance of substrates. Theoretically, to accurately estimate the overall f_m from metabolite formation data, one must measure the formation of all the metabolites. In particular, when using liver microsomes the contribution of enzymes located in cytosolic fraction or those whose enzymatic reaction requires certain cofactor(s) (e.g., phase II enzymes) cannot be considered, causing overestimation of the contribution of CYP enzymes. Another difficulty is that the activity of each CYP enzyme can be highly dependent on the study design, such as the selection of microsomes (pooled batch, individual batch) and the selection of the medium, including phosphate concentration (Crespi, 1998).

These aspects reinforce the importance of reliably establishing in vivo f_m for developing optimal in vitro experimental conditions. In an ideal scenario of drug development, it is also important to consider the outcomes of mass-balance studies for realizing definitive in vivo f_m estimates, but few data are publicly available at this time.

Our findings suggest an additional factor to consider when selecting probe substrates for clinical DDI studies to improve PBPK model-based parameter estimation. We showed that the specificity of enzymes involved in the formation of the metabolites was important in improving the reliability of f_m and K_i estimates. Current regulatory guidance/guidelines on pharmacokinetic drug interaction recommend conducting clinical DDI studies with in vivo probe substrates, with the predominant contribution of a single enzyme to their overall elimination (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf; <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf>; <https://www.pmda.go.jp/files/000225191.pdf>). To accurately determine the interaction potential of a new investigational drug as an inhibitor, the selection of substrates with metabolites formed by the specific enzyme of interest (e.g., substrates listed in Fig. 3A) can be important, in addition to other considerations such as likelihood of comedication.

In conclusion, this study demonstrated the importance of considering pharmacokinetic alterations of substrate metabolites as well as substrate parent drugs in the accurate determination of in vivo K_i and f_m using PBPK modeling. The obtained K_i values should increase the accuracy of the predicted degree of DDIs for untested combinations of substrates and inhibitors.

Authorship Contributions

Participated in research design: Yoshida, Maeda.

Conducted experiments: Yoshida, Maeda.

Contributed new reagents or analytic tools: Konagaya.

Performed data analysis: Yoshida, Maeda, Kusuhara.

Wrote or contributed to the writing of the manuscript: Yoshida, Maeda, Kusuhara.

References

- Aoki Y, Hayami K, Sterck HD, and Konagaya A (2014) Cluster Newton method for sampling multiple solutions of underdetermined inverse problems: application to a parameter identification problem in pharmacokinetics. *SIAM J Sci Comput* **36**:B14–B44.
- Arredondo G, Suárez E, Calvo R, Vazquez JA, García-Sánchez J, and Martínez-Jordá R (1999) Serum protein binding of itraconazole and fluconazole in patients with diabetes mellitus. *J Antimicrob Chemother* **43**:305–307.
- Benet LZ, Cummins CL, and Wu CY (2004) Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. *Int J Pharm* **277**:3–9.
- Brown HS, Ito K, Galetin A, and Houston JB (2005) Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. *Br J Clin Pharmacol* **60**:508–518.
- Ching MS, Blake CL, Ghabrial H, Ellis SW, Lennard MS, Tucker GT, and Smallwood RA (1995) Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites. *Biochem Pharmacol* **50**:833–837.
- Crespi CL (1998) Effect of salt concentration on the activity of liver microsomal and cDNA-expressed human cytochromes P450, in *International Symposium on Microsomes & Drug Oxidations*; Montpellier, France. pp 95.
- Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. *Pharm Res* **10**:1093–1095.
- Ekström G and Gunnarsson UB (1996) Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes. *Drug Metab Dispos* **24**:955–961.
- Fowler S and Zhang H (2008) In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. *AAPS J* **10**:410–424.
- Guillon J, Buronfosse T, Désage M, Lepape A, Brazier JL, and Beaune P (1997) Possible involvement of multiple cytochrome P450s in fentanyl and sufentanil metabolism as opposed to alfentanil. *Biochem Pharmacol* **53**:1613–1619.
- Hachad H, Ragueneau-Majlessi I, and Levy RH (2010) A useful tool for drug interaction evaluation: the University of Washington Metabolism and Transport Drug Interaction Database. *Hum Genomics* **5**:61–72.
- Hanley MJ, Masse G, Harmatz JS, Cancalon PF, Dolnikowski GG, Court MH, and Greenblatt DJ (2013) Effect of blueberry juice on clearance of buspirone and flurbiprofen in human volunteers. *Br J Clin Pharmacol* **75**:1041–1052.
- Hisaka A, Ohno Y, Yamamoto T, and Suzuki H (2010) Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. *Pharmacol Ther* **125**:230–248.
- Houston JB and Galetin A (2008) Methods for predicting in vivo pharmacokinetics using data from in vitro assays. *Curr Drug Metab* **9**:940–951.
- Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, et al. (2008) New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. *J Clin Pharmacol* **48**:662–670.
- Hutchinson MR, Menelau A, Foster DJ, Collier JK, and Somogyi AA (2004) CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. *Br J Clin Pharmacol* **57**:287–297.
- Isoherranen N, Hachad H, Yeung CK, and Levy RH (2009) Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database. *Chem Res Toxicol* **22**:294–298.
- Isoherranen N, Kunze KL, Allen KE, Nelson WL, and Thummel KE (2004) Role of itraconazole metabolites in CYP3A4 inhibition. *Drug Metab Dispos* **32**:1121–1131.
- Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. *Pharmacol Ther* **50**:387–412.
- Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, Snoeys J, Upreti VV, Zheng M, and Hall SD (2015) Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. *Clin Pharmacol Ther* **97**:247–262.
- Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, Ikeda T, and Sugiyama Y (2008) The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. *Pharm Res* **25**:1891–1901.
- Khojasteh SC, Wong H, and Hop CE (2011) Metabolism-based drug interactions, in *Drug Metabolism and Pharmacokinetics Quick Guide*, pp 73–95, Springer, New York.
- Lalovic B, Phillips B, Risler LL, Howald W, and Shen DD (2004) Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. *Drug Metab Dispos* **32**:447–454.
- Lutz JD and Isoherranen N (2012) In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors. *Expert Opin Drug Metab Toxicol* **8**:449–466.
- Luzon E, Blake K, Cole S, Nordmark A, Versantvoort C, and Berglund EG (2017) Physiologically based pharmacokinetic modeling in regulatory decision-making at the European Medicines Agency. *Clin Pharmacol Ther* **102**:98–105.
- McGinnity DF, Waters NJ, Tucker J, and Riley RJ (2008) Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions. *Drug Metab Dispos* **36**:1126–1134.
- Naritomi Y, Terashita S, and Kagayama A (2004) Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. *Xenobiotica* **34**:415–427.
- Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. *J Pharmacol Exp Ther* **316**:336–348.
- Otto SV, Wu D, Joffe RT, Cheung SW, and Sellers EM (1993) Inhibition by fluoxetine of cytochrome P450 2D6 activity. *Clin Pharmacol Ther* **53**:401–409.
- Rodgers T, Leahy D, and Rowland M (2005) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. *J Pharm Sci* **94**:1259–1276.
- Rodgers T and Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. *J Pharm Sci* **95**:1238–1257.
- Rowland M, Peck C, and Tucker G (2011) Physiologically-based pharmacokinetics in drug development and regulatory science. *Annu Rev Pharmacol Toxicol* **51**:45–73.
- Saari TI, Laine K, Neuvonen M, Neuvonen PJ, and Olkkola KT (2008) Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. *Eur J Clin Pharmacol* **64**:25–30.
- Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson WL, and Isoherranen N (2008) Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. *Clin Pharmacol Ther* **83**:77–85.
- Thompson KA, Murray JJ, Blair IA, Woosley RL, and Roden DM (1988) Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes. *Clin Pharmacol Ther* **43**:636–642.
- Thummel KE, Shen DD, and Isoherranen N. (2010) Design and optimization of dosage regimens: pharmacokinetic data, in *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 12th ed (Brunton LL, Chabner BA, and Knollmann BC eds), appendix II, McGraw-Hill, New York.
- Tono M, Konishi Y, Kojima H, Kawahara K, and Horiba M. (1992) Pharmacokinetics and metabolic studies of LFP83 in man after the single and repeated intravenous administration [in Japanese]. *Kiso to Rinsho* **26**:3907–3921.

- Wagner C, Zhao P, Pan Y, Hsu V, Grillo J, Huang SM, and Sinha V (2015) Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK. *CPT Pharmacometrics Syst Pharmacol* **4**: 226–230.
- Yamano K, Yamamoto K, Kotaki H, Sawada Y, and Iga T (1999) Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver. *Drug Metab Dispos* **27**:395–402.
- Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA, Guengerich FP, and Shimada T (1998) Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. *Biochem Pharmacol* **56**:243–251.
- Yoshida K, Maeda K, Kusuhara H, and Konagaya A (2013) Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models. *BMC Syst Biol* **7** (Suppl 3):S3.

Address correspondence to: Dr. Hiroyuki Kusuhara, Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. E-mail: kusuhara@mol.f.u-tokyo.ac.jp